Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Schönborn – page 6

1 165 clinical trials in Bad Schönborn, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Schönborn at a glance
1 165
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 165 trials in Bad Schönborn

Open in trial search

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Schönborn

What the registry says about research in the country

01 Chronic Sinusitis Research

Innovative clinical trials exploring LYR-210 depot therapy for patients with chronic rhinosinusitis who haven't responded to conventional treatments. This research focuses on improving the three cardinal symptoms of CRS in patients without nasal polyps.

  • Chronic Rhinosinusitis Management
  • Non-Polyp CRS Treatment
  • Alternative Therapeutic Approaches

Research aims to provide new options for patients who have exhausted traditional medical management strategies.

02 House Dust Mite Allergy Studies

Comprehensive evaluation of subcutaneous immunotherapy for moderate to severe allergic rhinitis and rhinoconjunctivitis. The research examines a specialized treatment protocol using PURETHAL Mites Mixture for patients with or without concurrent asthma.

  • Allergic Rhinitis Treatment
  • Immunotherapy Efficacy
  • Combined Symptom Management

This study measures treatment effectiveness through the Total Combined Rhinitis Score over a one-year period.

03 Seasonal Allergy Research

Investigation of PQ Birch therapy for seasonal allergic conditions, specifically targeting birch pollen-induced rhinitis and rhinoconjunctivitis. The research evaluates both safety and efficacy parameters.

  • Seasonal Rhinitis Treatment
  • Birch Pollen Allergies
  • Therapeutic Innovation

The study focuses on developing targeted solutions for seasonal allergy sufferers during birch pollen season.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.